Peter John Harrison Acquires 1,065 Shares of Bioventix (LON:BVXP) Stock

Key Points

• Insider purchase: Peter John Harrison acquired 1,065 shares of Bioventix on April 8 at an average price of GBX 1,849, costing £19,691.85 in total.
• Market context: Shares were trading at GBX 1,800 midday with above-average volume; the 50‑ and 200‑day moving averages are GBX 1,601.69 and GBX 1,887.75, the 52‑week range is GBX 1,300–3,020, and the company has a market cap of ~£94.05m with a PE of 12.81.
• Financials: Latest quarterly EPS was GBX 69.38 with a return on equity of 65.83% and a net margin of 59.30%, while analysts forecast about GBX 166.31 EPS for the current fiscal year.

Bioventix PLC (LON:BVXP - Get Free Report) insider Peter John Harrison bought 1,065 shares of the stock in a transaction dated Wednesday, April 8th. The shares were purchased at an average price of GBX 1,849 per share, with a total value of £19,691.85.

Bioventix Price Performance

Shares of LON BVXP remained flat at GBX 1,800 during midday trading on Friday. The stock had a trading volume of 19,195 shares, compared to its average volume of 11,064. The stock has a 50 day moving average of GBX 1,601.69 and a 200 day moving average of GBX 1,887.75. Bioventix PLC has a 52-week low of GBX 1,300 and a 52-week high of GBX 3,020. The company has a market capitalization of £94.05 million, a PE ratio of 12.81 and a beta of 0.48.

Bioventix (LON:BVXP - Get Free Report) last released its quarterly earnings results on Monday, March 30th. The biotechnology company reported GBX 69.38 earnings per share for the quarter. Bioventix had a return on equity of 65.83% and a net margin of 59.30%.The company had revenue of GBX 615.88 billion for the quarter. On average, equities research analysts forecast that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.